公开(公告)号：US09676797B2

公开(公告)日：2017-06-13

申请号：US15254342

申请日：2016-09-01

Applicant: AbbVie Inc.

Inventor： Hui-Ju J. Chen ,  David A. DeGoey ,  John Hartung ,  Nathan Ide ,  Vikram Kalthod ,  Allan C. Krueger ,  Yi-Yin Ku ,  Tongmei Li ,  John T. Randolph ,  Rolf Wagner ,  Jaclyn Chau ,  Geoff T. Halvorsen ,  Christopher C. Marvin ,  Eric Voight

IPC: A61K31/675 ,  C07F9/02 ,  C07F9/08 ,  C07F9/6512

CPC classification number: C07F9/08 ,  C07F9/6512 ,  C07H19/10

Abstract: The present invention features compounds effective in inhibiting active against Hepatitis C virus (“HCV”) polymerase. The invention also features processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

公开(公告)号：US20170157105A1

公开(公告)日：2017-06-08

申请号：US15434789

申请日：2017-02-16

Applicant: AbbVie Inc.

Inventor： Mary E. Bellizzi ,  David A. Betebenner ,  Jean-Christophe C. Califano ,  William A. Carroll ,  Daniel D. Caspi ,  David A. DeGoey ,  Pamela L. Donner ,  Charles A. Flentge ,  Yi Gao ,  Charles W. Hutchins ,  Douglas K. Hutchinson ,  Tammie K. Jinkerson ,  Warren M. Kati ,  Ryan G. Keddy ,  Allan C. Krueger ,  Wenke Li ,  Dachun Liu ,  Clarence J. Maring ,  Mark A. Matulenko ,  Christopher E. Motter ,  Lissa T. Nelson ,  Sachin V. Patel ,  John K. Pratt ,  John T. Randolph ,  Todd W. Rockway ,  Kathy Sarris ,  Michael D. Tufano ,  Seble H. Wagaw ,  Rolf Wagner ,  Kevin R. Woller

IPC: A61K31/695

CPC classification number: A61K31/454 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/422 ,  A61K31/435 ,  A61K31/4355 ,  A61K31/438 ,  A61K31/4418 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/695 ,  A61K45/06 ,  C07D401/14 ,  C07D403/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D453/00 ,  C07D491/113 ,  C07F7/02 ,  Y02P20/582

Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

公开(公告)号：US20160368905A1

公开(公告)日：2016-12-22

申请号：US15141556

申请日：2016-04-28

Applicant: AbbVie Inc.

Inventor： David A. Betebenner ,  John K. Pratt ,  David A. DeGoey ,  Pamela L. Donner ,  Charles A. Flentge ,  Douglas K. Hutchinson ,  Warren M. Kati ,  Allan C. Krueger ,  Kenton L. Longenecker ,  Clarence J. Maring ,  John T. Randolph ,  Todd W. Rockway ,  Michael D. Tufano ,  Rolf Wagner ,  Dachun Liu

IPC: C07D409/10 ,  A61K31/513 ,  C07D213/64 ,  A61K31/4418 ,  C07C311/08 ,  A61K31/18 ,  C07D233/72 ,  A61K31/4166 ,  A61K31/27 ,  C07D263/24 ,  A61K31/421 ,  C07D239/10 ,  C07D207/27 ,  A61K31/402 ,  C07D405/10 ,  C07D403/10 ,  A61K45/06 ,  A61K31/425 ,  C07D275/02 ,  C07D239/54

CPC classification number: C07D409/10 ,  A61K31/18 ,  A61K31/27 ,  A61K31/402 ,  A61K31/4166 ,  A61K31/421 ,  A61K31/425 ,  A61K31/4418 ,  A61K31/503 ,  A61K31/513 ,  A61K45/06 ,  C07C311/08 ,  C07D207/27 ,  C07D213/64 ,  C07D233/32 ,  C07D233/72 ,  C07D239/10 ,  C07D239/54 ,  C07D263/22 ,  C07D263/24 ,  C07D275/02 ,  C07D403/10 ,  C07D405/10 ,  Y02P20/55

Abstract: This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.

Abstract translation: 本发明涉及：（a）特别是抑制HCV的化合物及其盐; （b）可用于制备这些化合物和盐的中间体; （c）包含这些化合物和盐的组合物; （d）制备这种中间体，化合物，盐和组合物的方法; （e）使用这些化合物，盐和组合物的方法; 和（f）包含这些化合物，盐和组合物的试剂盒。

公开(公告)号：US09249138B2

公开(公告)日：2016-02-02

申请号：US14017901

申请日：2013-09-04

Applicant: ABBVIE INC.

Inventor： David A. Degoey ,  Pamela L. Donner ,  Warren M. Kati ,  Charles W. Hutchins ,  Allan C. Krueger ,  John T. Randolph ,  Christopher E. Motter ,  Preethi Krishnan ,  Neeta C. Mistry ,  Tami J. Pilot-Matias ,  Sachin V. Patel ,  Xiaoyan Li ,  Todd N. Soltwedel ,  Lissa T. Nelson

IPC: C07D239/48 ,  C07D471/04

CPC classification number: C07D471/04 ,  C07D239/48

Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

公开(公告)号：US09139536B2

公开(公告)日：2015-09-22

申请号：US13838223

申请日：2013-03-15

Applicant: AbbVie Inc.

Inventor： Charles A. Flentge ,  Douglas K. Hutchinson ,  David A. Betebenner ,  David A. DeGoey ,  Pamela L. Donner ,  Warren M. Kati ,  Allan C. Krueger ,  Dachun Liu ,  Yaya Liu ,  Kenton L. Longenecker ,  Clarence J. Maring ,  Christopher E. Motter ,  John K. Pratt ,  John T. Randolph ,  Todd W. Rockway ,  Kent D. Stewart ,  Rolf Wagner ,  Shuang Chen ,  Yi Gao ,  Xiaochun Lou ,  Geoff G. Z. Zhang

IPC: A61K31/505 ,  C07D239/54 ,  C07D239/22 ,  C07D401/10 ,  C07D403/10 ,  C07D405/10 ,  C07D409/10 ,  C07D413/10 ,  C07D417/10 ,  A61K31/513 ,  A61K45/06

CPC classification number: C07D239/54 ,  A61K31/513 ,  A61K45/06 ,  C07D239/22 ,  C07D401/10 ,  C07D403/10 ,  C07D405/10 ,  C07D409/10 ,  C07D413/10 ,  C07D417/10 ,  A61K2300/00

Abstract: This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.

Abstract translation: 本发明涉及：（a）特别是抑制HCV的化合物及其盐; （b）可用于制备这些化合物和盐的中间体; （c）包含这些化合物和盐的组合物; （d）制备这种中间体，化合物，盐和组合物的方法; （e）使用这些化合物，盐和组合物的方法; 和（f）包含这些化合物，盐和组合物的试剂盒。

公开(公告)号：US20150225409A1

公开(公告)日：2015-08-13

申请号：US14693419

申请日：2015-04-22

Applicant: AbbVie Inc.

Inventor： Pramila A. Bhatia ,  John T. Randolph ,  Michael R. Schrimpf ,  Qingwei I. Zhang

IPC: C07D487/04

CPC classification number: C07D487/04

Abstract: This invention relates to: (a) compounds and salts thereof that, inter alia, treat pain; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.

Abstract translation: 本发明涉及：（a）其特别是治疗疼痛的化合物及其盐; （b）可用于制备这些化合物和盐的中间体; （c）包含这些化合物和盐的组合物; （d）制备这种中间体，化合物，盐和组合物的方法; （e）使用这些化合物，盐和组合物的方法; 和（f）包含这些化合物，盐和组合物的试剂盒。

公开(公告)号：US20140294766A1

公开(公告)日：2014-10-02

申请号：US13838223

申请日：2013-03-15

Applicant: AbbVie Inc.

Inventor： Charles A. Flentge ,  Douglas K. Hutchinson ,  David A. Betebenner ,  David A. DeGoey ,  Pamela L. Donner ,  Warren M. Kati ,  Allan C. Krueger ,  Dachun Liu ,  Yaya Liu ,  Kenton L. Longenecker ,  Clarence J. Maring ,  Christopher E. Motter ,  John K. Pratt ,  John T. Randolph ,  Todd W. Rockway ,  Kent D. Stewart ,  Rolf Wagner ,  Shuang Chen ,  Yi Gao ,  Xiaochun Lou ,  Geoff G.Z. Zhang

IPC: C07D239/54 ,  A61K45/06 ,  A61K31/513

CPC classification number: C07D239/54 ,  A61K31/513 ,  A61K45/06 ,  C07D239/22 ,  C07D401/10 ,  C07D403/10 ,  C07D405/10 ,  C07D409/10 ,  C07D413/10 ,  C07D417/10 ,  A61K2300/00

Abstract: This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.

Abstract translation: 本发明涉及：（a）特别是抑制HCV的化合物及其盐; （b）可用于制备这些化合物和盐的中间体; （c）包含这些化合物和盐的组合物; （d）制备这种中间体，化合物，盐和组合物的方法; （e）使用这些化合物，盐和组合物的方法; 和（f）包含这些化合物，盐和组合物的试剂盒。

公开(公告)号：US20140243340A1

公开(公告)日：2014-08-28

申请号：US14273182

申请日：2014-05-08

Applicant: AbbVie Inc.

Inventor： Larry L. Klein ,  Hui-Ju CHEN ,  Ming C. YEUNG ,  Charles A. Flentge ,  John T. Randolph ,  Peggy Huang ,  Douglas K. Hutchinson ,  Dale J. Kempf

IPC: A61K31/5377 ,  A61K31/4439 ,  A61K31/4178 ,  A61K45/06 ,  A61K31/4164 ,  A61K31/506 ,  A61K31/496 ,  A61K31/4525 ,  C07D417/12 ,  C07D277/30

CPC classification number: A61K31/5377 ,  A61K31/4164 ,  A61K31/4178 ,  A61K31/4439 ,  A61K31/4525 ,  A61K31/496 ,  A61K31/506 ,  A61K45/06 ,  C07D213/79 ,  C07D277/24 ,  C07D277/30 ,  C07D277/593 ,  C07D417/12

Abstract: The present invention features compounds of formula I or pharmaceutically acceptable salts, solvates or prodrugs thereof, and methods of using the same to inhibit the metabolizing activities of CYP enzymes. The present invention also features methods of using these compounds, salts, solvates or prodrugs to improve the pharmacokinetics of drugs that are metabolized by CYP enzymes.

Abstract translation: 本发明的特征在于式I化合物或其药学上可接受的盐，溶剂合物或前药，以及使用该化合物抑制CYP酶代谢活性的方法。 本发明还涉及使用这些化合物，盐，溶剂合物或前药来改善由CYP酶代谢的药物的药代动力学的方法。